Ligand Pharmaceuticals LGND Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's return on equity?
- Ligand Pharmaceuticals (LGND) reported return on equity of 17.1% in Q1 2026.
- How has Ligand Pharmaceuticals's return on equity changed year-over-year?
- Ligand Pharmaceuticals's return on equity increased by 203.5% year-over-year, from -16.6% to 17.1%.
- What is the long-term trend for Ligand Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's return on equity has grown at a 101.6% compound annual growth rate (CAGR), from -0.4% to 13.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.